Radiotheranostics Market By Radioisotope (Lutetium-177, Gallium-68, Iodine-131, Actinium-225, Others), By Application (Oncology, Cardiology, Neurology, Others.), By End-user (Hospitals, Diagnostic Imaging Centers, Cancer Research Institutes, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035
Published Date: Jun 2025 | Report ID: MI2969 | 219 Pages
Table of Contents
1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Radiotheranostics Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Rising incidence of neuroendocrine and prostate cancers requiring targeted treatment solutions.
3.2.2. Growing use of personalized medicine driving demand for dual diagnostic-therapeutic tools.
3.2.3. Increasing FDA and EMA approvals of radiotheranostic agents like Lutathera and Pluvicto.
3.3. Key industry pitfalls & challenges
3.3.1. High cost of radiopharmaceuticals and therapies, limiting accessibility in low-resource settings.
3.3.2. Short half-life of certain radioisotopes, complicating logistics and storage.
3.3.3. Strict regulatory requirements for isotope handling and therapy approvals.
3.4. Market Opportunities
3.4.1. Expansion into non-oncology applications, like cardiology and neurology.
3.4.2. Partnerships between pharma companies and academic institutions for R&D acceleration.
3.4.3. Integration with AI in imaging interpretation for more precise diagnostics.
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Investment landscape
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. Radiotheranostics Market, Radioisotope Segment Analysis
4.1. Overview of Dynamics
4.1.1. Market Revenue Share, By Radioisotope, 2025 & 2035
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Lutetium-177
4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)
4.3. Gallium-68
4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)
4.4. Iodine-131
4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)
4.5. Actinium-225
4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)
4.6. Others
4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)
5. Radiotheranostics Market, Application Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Application, 2025 & 2035
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Oncology
5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)
5.3. Cardiology
5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)
5.4. Neurology
5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)
5.5. Others
5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)
6. Radiotheranostics Market, End-user Segment Analysis
6.1. Overview
6.1.1. Market Revenue Share, By End-user, 2025 & 2035
6.1.2. Key Market Trends, Growth Factors, & Opportunities
6.2. Hospitals
6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)
6.3. Diagnostic Imaging Centres
6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)
6.4. Cancer Research Institutes
6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)
6.5. Specialty Clinics
6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)
6.6. Others
6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)
7. Radiotheranostics Market, Region Segment Analysis
7.1. Overview
7.1.1. Global Market Revenue Share, By Region, 2025 & 2035
7.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)
7.2. North America
7.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)
7.2.2. North America Market Revenue, By Radioisotope, 2025-2035
7.2.3. North America Market Revenue, By Application, 2025-2035
7.2.4. North America Market Revenue, By End-user, 2025-2035
7.2.5. The U.S.
7.2.5.1. U.S. Market Revenue, By Radioisotope, 2025-2035
7.2.5.2. U.S. Market Revenue, By Application, 2025-2035
7.2.5.3. U.S. Market Revenue, By End-user, 2025-2035
7.2.6. Canada
7.2.6.1. Canada Market Revenue, By Radioisotope, 2025-2035
7.2.6.2. Canada Market Revenue, By Application, 2025-2035
7.2.6.3. Canada Market Revenue, By End-user, 2025-2035
7.3. Europe
7.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)
7.3.2. Europe Market Revenue, By Radioisotope, 2025-2035
7.3.3. Europe Market Revenue, By Application, 2025-2035
7.3.4. Europe Market Revenue, By End-user, 2025-2035
7.3.5. Germany
7.3.5.1. Germany Market Revenue, By Radioisotope, 2025-2035
7.3.5.2. Germany Market Revenue, By Application, 2025-2035
7.3.5.3. Germany Market Revenue, By End-user, 2025-2035
7.3.6. France
7.3.6.1. France Market Revenue, By Radioisotope, 2025-2035
7.3.6.2. France Market Revenue, By Application, 2025-2035
7.3.6.3. France Market Revenue, By End-user, 2025-2035
7.3.7. U.K.
7.3.7.1. U.K. Market Revenue, By Radioisotope, 2025-2035
7.3.7.2. U.K. Market Revenue, By Application, 2025-2035
7.3.7.3. U.K. Market Revenue, By End-user, 2025-2035
7.3.8. Italy
7.3.8.1. Italy Market Revenue, By Radioisotope, 2025-2035
7.3.8.2. Italy Market Revenue, By Application, 2025-2035
7.3.8.3. Italy Market Revenue, By End-user, 2025-2035
7.3.9. Spain
7.3.9.1. Spain Market Revenue, By Radioisotope, 2025-2035
7.3.9.2. Spain Market Revenue, By Application, 2025-2035
7.3.9.3. Spain Market Revenue, By End-user, 2025-2035
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe Market Revenue, By Radioisotope, 2025-2035
7.3.10.2. Rest of Europe Market Revenue, By Application, 2025-2035
7.3.10.3. Rest of Europe Market Revenue, By End-user, 2025-2035
7.4. Asia Pacific
7.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)
7.4.2. Asia Pacific Market Revenue, By Radioisotope, 2025-2035
7.4.3. Asia Pacific Market Revenue, By Application, 2025-2035
7.4.4. Asia Pacific Market Revenue, By End-user, 2025-2035
7.4.5. China
7.4.5.1. China Market Revenue, By Radioisotope, 2025-2035
7.4.5.2. China Market Revenue, By Application, 2025-2035
7.4.5.3. China Market Revenue, By End-user, 2025-2035
7.4.6. Japan
7.4.6.1. Japan Market Revenue, By Radioisotope, 2025-2035
7.4.6.2. Japan Market Revenue, By Application, 2025-2035
7.4.6.3. Japan Market Revenue, By End-user, 2025-2035
7.4.7. India
7.4.7.1. India Market Revenue, By Radioisotope, 2025-2035
7.4.7.2. India Market Revenue, By Application, 2025-2035
7.4.7.3. India Market Revenue, By End-user, 2025-2035
7.4.8. Australia
7.4.8.1. Australia Market Revenue, By Radioisotope, 2025-2035
7.4.8.2. Australia Market Revenue, By Application, 2025-2035
7.4.8.3. Australia Market Revenue, By End-user, 2025-2035
7.4.9. South Korea
7.4.9.1. South Korea Market Revenue, By Radioisotope, 2025-2035
7.4.9.2. South Korea Market Revenue, By Application, 2025-2035
7.4.9.3. South Korea Market Revenue, By End-user, 2025-2035
7.4.10. Singapore
7.4.10.1. Singapore Market Revenue, By Radioisotope, 2025-2035
7.4.10.2. Singapore Market Revenue, By Application, 2025-2035
7.4.10.3. Singapore Market Revenue, By End-user, 2025-2035
7.4.11. Rest of Asia Pacific
7.4.11.1. Rest of Asia Pacific Market Revenue, By Radioisotope, 2025-2035
7.4.11.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035
7.4.11.3. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035
7.5. Latin America
7.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)
7.5.2. Latin America Market Revenue, By Radioisotope, 2025-2035
7.5.3. Latin America Market Revenue, By Application, 2025-2035
7.5.4. Latin America Market Revenue, By End-user, 2025-2035
7.5.5. Brazil
7.5.5.1. Brazil Market Revenue, By Radioisotope, 2025-2035
7.5.5.2. Brazil Market Revenue, By Application, 2025-2035
7.5.5.3. Brazil Market Revenue, By End-user, 2025-2035
7.5.6. Argentina
7.5.6.1. Argentina Market Revenue, By Radioisotope, 2025-2035
7.5.6.2. Argentina Market Revenue, By Application, 2025-2035
7.5.6.3. Argentina Market Revenue, By End-user, 2025-2035
7.5.7. Mexico
7.5.7.1. Mexico Market Revenue, By Radioisotope, 2025-2035
7.5.7.2. Mexico Market Revenue, By Application, 2025-2035
7.5.7.3. Mexico Market Revenue, By End-user, 2025-2035
7.5.8. Rest of Latin America
7.5.8.1. Rest of Latin America Market Revenue, By Radioisotope, 2025-2035
7.5.8.2. Rest of Latin America Market Revenue, By Application, 2025-2035
7.5.8.3. Rest of Latin America Market Revenue, By End-user, 2025-2035
7.6. MEA
7.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)
7.6.2. MEA Market Revenue, By Radioisotope, 2025-2035
7.6.3. MEA Market Revenue, By Application, 2025-2035
7.6.4. MEA Market Revenue, By End-user, 2025-2035
7.6.5. GCC Countries
7.6.5.1. GCC Countries Market Revenue, By Radioisotope, 2025-2035
7.6.5.2. GCC Countries Market Revenue, By Application, 2025-2035
7.6.5.3. GCC Countries Market Revenue, By End-user, 2025-2035
7.6.6. South Africa
7.6.6.1. South Africa Market Revenue, By Radioisotope, 2025-2035
7.6.6.2. South Africa Market Revenue, By Application, 2025-2035
7.6.6.3. South Africa Market Revenue, By End-user, 2025-2035
7.6.7. Rest of Middle-East & Africa
7.6.7.1. Rest of Middle-East & Africa Market Revenue, By Radioisotope, 2025-2035
7.6.7.2. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035
7.6.7.3. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035
8. Company Profile
8.1. Novartis AG
8.1.1. Business Overview
8.1.2. Financial Performance
8.1.3. Product/Service Offerings
8.1.4. Strategies & recent developments
8.1.5. SWOT Analysis
8.2. Telix Pharmaceuticals Limited
8.2.1. Business Overview
8.2.2. Financial Performance
8.2.3. Product/Service Offerings
8.2.4. Strategies & recent developments
8.2.5. SWOT Analysis
8.3. Curium
8.3.1. Business Overview
8.3.2. Financial Performance
8.3.3. Product/Service Offerings
8.3.4. Strategies & recent developments
8.3.5. SWOT Analysis
8.4. Cardinal Health, Inc.
8.4.1. Business Overview
8.4.2. Financial Performance
8.4.3. Product/Service Offerings
8.4.4. Strategies & recent developments
8.4.5. SWOT Analysis
8.5. GE HealthCare
8.5.1. Business Overview
8.5.2. Financial Performance
8.5.3. Product/Service Offerings
8.5.4. Strategies & recent developments
8.5.5. SWOT Analysis
8.6. Lantheus Holdings, Inc.
8.6.1. Business Overview
8.6.2. Financial Performance
8.6.3. Product/Service Offerings
8.6.4. Strategies & recent developments
8.6.5. SWOT Analysis
8.7. ITM Isotope Technologies Munich SE
8.7.1. Business Overview
8.7.2. Financial Performance
8.7.3. Product/Service Offerings
8.7.4. Strategies & recent developments
8.7.5. SWOT Analysis
8.8. Eckert & Ziegler Strahlen- und Medizintechnik AG
8.8.1. Business Overview
8.8.2. Financial Performance
8.8.3. Product/Service Offerings
8.8.4. Strategies & recent developments
8.8.5. SWOT Analysis
8.9. Jubilant Radiopharma
8.9.1. Business Overview
8.9.2. Financial Performance
8.9.3. Product/Service Offerings
8.9.4. Strategies & recent developments
8.9.5. SWOT Analysis
8.10. Bayer AG
8.10.1. Business Overview
8.10.2. Financial Performance
8.10.3. Product/Service Offerings
8.10.4. Strategies & recent developments
8.10.5. SWOT Analysis
8.11. Theragnostics Ltd
8.11.1. Business Overview
8.11.2. Financial Performance
8.11.3. Product/Service Offerings
8.11.4. Strategies & recent developments
8.11.5. SWOT Analysis
8.12. NorthStar Medical Radioisotopes, LLC
8.12.1. Business Overview
8.12.2. Financial Performance
8.12.3. Product/Service Offerings
8.12.4. Strategies & recent developments
8.12.5. SWOT Analysis
8.13. Advanced Accelerator Applications S.A.
8.13.1. Business Overview
8.13.2. Financial Performance
8.13.3. Product/Service Offerings
8.13.4. Strategies & recent developments
8.13.5. SWOT Analysis
8.14. Bracco Imaging S.p.A.
8.14.1. Business Overview
8.14.2. Financial Performance
8.14.3. Product/Service Offerings
8.14.4. Strategies & recent developments
8.14.5. SWOT Analysis
8.15. Alpha Tau Medical Ltd.
8.15.1. Business Overview
8.15.2. Financial Performance
8.15.3. Product/Service Offerings
8.15.4. Strategies & recent developments
8.15.5. SWOT Analysis
Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!
Our analysts are ready to help you immediately.